Litcius/Paper detail

Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients

Evelina Cardoso, Monia Guidi, Nihel Khoudour, Pascaline Boudou‐Rouquette, Elizabeth Fabre, Camille Tlemsani, Jennifer Arrondeau, François Goldwasser, Michel Vidal, Marie Paule Schneider, Dorothea Wagner, Nicolas Widmer, Benoı̂t Blanchet, Chantal Csajka

2020Clinical Therapeutics17 citationsDOI

Topics & Concepts

ErlotinibMedicinePharmacokineticsLung cancerErlotinib HydrochlorideNONMEMDosingPopulationTherapeutic drug monitoringOncologyInternal medicinePharmacologyEpidermal growth factor receptorTyrosine-kinase inhibitorCancerEnvironmental healthLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients | Litcius